arrow
L

Lawrence I. Karsh

adventist health services
H指数:28
被引数:7,724

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A phase II study of the first-in-class oral innate immune activator BXCL701 with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC): Long-term follow-up

一类口服先天免疫激活剂BXCL701联合帕博利珠单抗治疗转移性去势抵抗性前列腺癌(mCRPC)患者的II期研究:长期随访

2024-09-010
PRE
Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer

SPARTAN和TITAN晚期前列腺癌患者快速和深度前列腺特异性抗原下降和患者报告的健康相关生活质量的事后分析

2024-08-015
PRE
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial

膀胱内Nadofaragene Firadenovec对卡介苗无反应的非肌层浸润性膀胱癌患者的疗效: 一项3期试验的5年随访

2024-07-0120
OA
TMPRSS2-ERG and RB1 as candidate predictive biomarkers for efficacy in TALAPRO-2: Phase 3 study of talazoparib (TALA) plus enzalutamide (ENZA) vs placebo (PBO) plus ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
2024-04-053
PRE
Development and Optimization of a Subtraction-Normalized Immunocyte Profiling Signature for Prostate Cancer Active Surveillance Risk Stratification
2024-03-010
OA
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN
2023-11-114
OAAI
Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Subgroup analyses of the all-comers cohort from TALAPRO-2 by homologous recombination repair (HRR) status

Talazoparib (TALA) 加恩扎鲁他胺 (ENZA) 治疗转移性去势抵抗性前列腺癌 (mCRPC): 通过同源重组修复 (HRR) 状态对来自TALAPRO-2的所有参与者队列进行亚组分析

2023-10-010
OA
A prospective study to determine the prevalence of DNA repair defects in patients (pts) with advanced prostate cancer (PC)

一项前瞻性研究,以确定晚期前列腺癌 (PC) 患者 (pts) 中DNA修复缺陷的患病率

2023-10-011
PRE
Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

Sipuleucel-t和醋酸阿比特龙或恩扎鲁他胺联合治疗转移性去势抵抗性前列腺癌: STAMP和STRIDE试验

2023-04-145
OAAI
Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial
2022-03-0113
OA